AI-native biotech research
Your thesis. Compiled.
Most biotech platforms put AI on top of a database. BioSniper built the data, source links, and research workflow for AI—so your criteria can be checked across every covered biotech company, with sources.
See supported fields and evidence rules. How we verify →
Below is an actual stored company decision from Spotter; the executed checks, findings, and source evidence are shown together, with no login required.
Rocket Pharmaceuticals Inc. is a late-stage biotechnology company developing lentiviral (LV) and adeno-associated virus (AAV) gene therapies for rare, monogenic diseases, with a focus on Fanconi Anemia and cardiovascular indications. It has no approved products and reported a net loss of $223.1M in 2025.
- Rocket Pharmaceuticals is advancing clinical programs for rare monogenic diseases, including Fanconi Anemia (RP-L102) and a Phase 2 pivotal trial design agreement for RP-L301 in PKD [sec · filed 2025-04-30].
- The company operates a ~100,000 sq. ft. AAV cGMP manufacturing facility in Cranbury, New Jersey for clinical and future commercial needs [sec · filed 2026-04-06].
- As of 2026-06-30, Rocket reported cash & equivalents of $224.5M and shareholders' equity of $368.8M; net income for the six months ended June 30, 2026 was $123.2M, boosted by a Priority Review Voucher (PRV) sale for $178.2M [sec · as of 2026-08-10] [latest reported financials].
- The company has an accumulated deficit of $1.44 billion as of December 31, 2025 and has never generated product revenue [sec_mda · as of 2026-02-26].
- Leadership has a track record of over 20 successful U.S. and international drug approvals and launches in cell and gene therapies [sec · filed 2026-04-06].
What works
- Rocket has a diversified pipeline targeting multiple rare monogenic diseases with both LV and AAV platforms, including a BLA submission for RP-L102 underway [sec · filed 2025-04-30] [sec_mda · as of 2026-02-26].
- The company operates its own U.S.-based cGMP manufacturing facility, reducing reliance on contract manufacturers and supporting scale-up [sec · filed 2026-04-06].
- A PRV sale yielded $178.2M in other income, strengthening the balance sheet; cash stood at $224.5M as of 2026-06-30 [sec_mda · as of 2026-08-10] [latest reported financials].
What to weigh
- Rocket has never generated product revenue and reported an accumulated deficit of $1.44 billion as of December 31, 2025 [sec_mda · as of 2026-02-26].
- Despite a Phase 2 pivotal trial design agreement for RP-L301 (PKD), the company has not initiated enrollment as it focuses resources on other programs [sec · filed 2025-04-30].
- Clinical development and regulatory approval for gene therapies carry inherent uncertainty; the company expects R&D expenses to increase [sec_mda · as of 2026-02-26].
From the filings
Quoted directly from source documents.
The company has no approved products and has not generated product revenue.
“We do not have any products approved for sale and have not generated any revenue from product sales.”
SEC MD&A · August 7, 2025
Accumulated deficit and net loss figures.
“have an accumulated deficit of $1.44 billion as of December 31, 2025.”
SEC MD&A · February 26, 2026
Sale of a Priority Review Voucher contributed significant other income.
“The increase in other income was primarily driven by the sale of the PRV for net $178.2 million.”
SEC MD&A · August 10, 2026
Managements expertise in drug approvals.
“Our leadership team brings a proven track record of over 20 successful U.S. and international drug approvals and launches with expertise in cell and gene therapies and rare diseases.”
SEC filings · April 6, 2026
Risks & what to watch (4)›
Key risks
- No approved products or revenue — Company has never generated product revenue; accumulated deficit of $1.44B as of Dec 31, 2025 [sec_mda].
- Clinical development uncertainty — Gene therapy development is risky; efficacy, regulatory, and manufacturing challenges remain [sec_mda].
- Dependence on financing — Ongoing operating losses and negative cash flows require additional financing to sustain operations [sec_mda].
- Regulatory pathway delays — BLA and MAA submissions are pending; delays or adverse decisions could impair pipeline [sec].
What to watch
- Progress of the BLA submission for RP-L102 (Fanconi Anemia) and EMA MAA decision [sec · filed 2025-04-30].
- Initiation of the Phase 2 pivotal trial for RP-L301 in PKD, which is designed but not yet enrolling [sec · filed 2025-04-30].
- Cash runway and whether the PRV sale extends operations beyond current projections; cash of $224.5M as of 2026-06-30 [latest reported financials].
- Updates on AAV-based cardiovascular gene therapy programs (RP-A501, RP-A602, RP-A702) targeting cardiomyopathies [sec_mda · as of 2026-02-26].
Sources: SEC filings · SEC MD&A · Generated September 13, 2026 · How we verify sources →
Built on the records biotech decisions depend on.
922 companies across 7 authoritative source families, normalized so your protocol can reason across finance, trials, regulation, science, and market context.
Company fundamentals
SEC filings, runway, and financing
Clinical development
Programs, trials, endpoints, and readouts
Regulatory + science
FDA, PubMed, and patent records
Market + event context
Prices, news, and catalysts across 922 companies
Biotech Pulse
Live market · upcoming catalysts · curated insights — all at a glance.
XBI
$161.27+1.92%
IBB
$209.11+0.94%
New Trials Initiated
5,677
FDA Approvals
382
Partnership Deals
29,318
Phase 3 Completion
33%
Upcoming FDA Catalysts
PDUFA dates, AdCom meetings, readouts — free, no login.
Recent M&A
AI-native, from the data up
Not AI added to a database. A research system built for AI.
Tell BioSniper what matters. It checks every covered biotech company and shows the evidence—so you do not have to research them one by one.